Cargando…
Risk Factor Assessment of Lymph Node Metastasis in Patients With FIGO Stage IB1 Cervical Cancer
OBJECTIVES: To assess the risk factors of lymph node metastasis (LNM) in patients with FIGO stage (2009) IB1 cervical cancer (CC). METHODS: Patients with FIGO stage IB1 CC who underwent radical resection between 2012 and 2018 were recruited. The risk factors for LNM were analysed. A recursive partit...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9007329/ https://www.ncbi.nlm.nih.gov/pubmed/35433446 http://dx.doi.org/10.3389/fonc.2022.809159 |
_version_ | 1784686823481540608 |
---|---|
author | Xu, Mu Xie, Xiaoyan Cai, Liangzhi Xie, Yongjin Gao, Qiao Sun, Pengming |
author_facet | Xu, Mu Xie, Xiaoyan Cai, Liangzhi Xie, Yongjin Gao, Qiao Sun, Pengming |
author_sort | Xu, Mu |
collection | PubMed |
description | OBJECTIVES: To assess the risk factors of lymph node metastasis (LNM) in patients with FIGO stage (2009) IB1 cervical cancer (CC). METHODS: Patients with FIGO stage IB1 CC who underwent radical resection between 2012 and 2018 were recruited. The risk factors for LNM were analysed. A recursive partitioning analysis (RPA) was used to divide the patients into risk groups and assess their risk of LNM. RESULTS: The 5-year overall survival rate was 91.72%, while 80.0% and 93.5% for patients with or without LNM (P<0.05). Multivariable logistic regression analysis showed that lymphovascular invasion (LVI), depth of invasion (DI), tumour size (TS), squamous cell carcinoma (SCC) antigen level were independent risk factors (all P<0.05). Patients were divided into low-risk (no LVI, DI <1/2, TS <2 cm), intermediate-risk (no LVI, DI <1/2, TS ≥2 cm; no LVI, DI ≥1/2, normal SCC level; LVI, DI <1/2, TS <2 cm), and high-risk (no LVI, DI ≥1/2, SCC level ≥1.5 ng/ml; LVI, TS <2 cm, DI ≥1/2; LVI, TS ≥2 cm) groups by RPA according to these four factors. The incidence of LNM among the three groups was 0.00%, 4.40%, and 24.10%, respectively (all P<0.001). The 5-year overall survival rates differed among the groups (98.2%, 92.7%, 83.0%, respectively, P=0.001). CONCLUSIONS: LNM affects the prognosis of patients with FIGO stage IB1 CC. Lymphadenectomy may be avoided for patients in the low-risk group and recommended for those in the high-risk group. Whether dissection is performed in the intermediate-risk group depends on the lymph node biopsy results. |
format | Online Article Text |
id | pubmed-9007329 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90073292022-04-14 Risk Factor Assessment of Lymph Node Metastasis in Patients With FIGO Stage IB1 Cervical Cancer Xu, Mu Xie, Xiaoyan Cai, Liangzhi Xie, Yongjin Gao, Qiao Sun, Pengming Front Oncol Oncology OBJECTIVES: To assess the risk factors of lymph node metastasis (LNM) in patients with FIGO stage (2009) IB1 cervical cancer (CC). METHODS: Patients with FIGO stage IB1 CC who underwent radical resection between 2012 and 2018 were recruited. The risk factors for LNM were analysed. A recursive partitioning analysis (RPA) was used to divide the patients into risk groups and assess their risk of LNM. RESULTS: The 5-year overall survival rate was 91.72%, while 80.0% and 93.5% for patients with or without LNM (P<0.05). Multivariable logistic regression analysis showed that lymphovascular invasion (LVI), depth of invasion (DI), tumour size (TS), squamous cell carcinoma (SCC) antigen level were independent risk factors (all P<0.05). Patients were divided into low-risk (no LVI, DI <1/2, TS <2 cm), intermediate-risk (no LVI, DI <1/2, TS ≥2 cm; no LVI, DI ≥1/2, normal SCC level; LVI, DI <1/2, TS <2 cm), and high-risk (no LVI, DI ≥1/2, SCC level ≥1.5 ng/ml; LVI, TS <2 cm, DI ≥1/2; LVI, TS ≥2 cm) groups by RPA according to these four factors. The incidence of LNM among the three groups was 0.00%, 4.40%, and 24.10%, respectively (all P<0.001). The 5-year overall survival rates differed among the groups (98.2%, 92.7%, 83.0%, respectively, P=0.001). CONCLUSIONS: LNM affects the prognosis of patients with FIGO stage IB1 CC. Lymphadenectomy may be avoided for patients in the low-risk group and recommended for those in the high-risk group. Whether dissection is performed in the intermediate-risk group depends on the lymph node biopsy results. Frontiers Media S.A. 2022-03-30 /pmc/articles/PMC9007329/ /pubmed/35433446 http://dx.doi.org/10.3389/fonc.2022.809159 Text en Copyright © 2022 Xu, Xie, Cai, Xie, Gao and Sun https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Xu, Mu Xie, Xiaoyan Cai, Liangzhi Xie, Yongjin Gao, Qiao Sun, Pengming Risk Factor Assessment of Lymph Node Metastasis in Patients With FIGO Stage IB1 Cervical Cancer |
title | Risk Factor Assessment of Lymph Node Metastasis in Patients With FIGO Stage IB1 Cervical Cancer |
title_full | Risk Factor Assessment of Lymph Node Metastasis in Patients With FIGO Stage IB1 Cervical Cancer |
title_fullStr | Risk Factor Assessment of Lymph Node Metastasis in Patients With FIGO Stage IB1 Cervical Cancer |
title_full_unstemmed | Risk Factor Assessment of Lymph Node Metastasis in Patients With FIGO Stage IB1 Cervical Cancer |
title_short | Risk Factor Assessment of Lymph Node Metastasis in Patients With FIGO Stage IB1 Cervical Cancer |
title_sort | risk factor assessment of lymph node metastasis in patients with figo stage ib1 cervical cancer |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9007329/ https://www.ncbi.nlm.nih.gov/pubmed/35433446 http://dx.doi.org/10.3389/fonc.2022.809159 |
work_keys_str_mv | AT xumu riskfactorassessmentoflymphnodemetastasisinpatientswithfigostageib1cervicalcancer AT xiexiaoyan riskfactorassessmentoflymphnodemetastasisinpatientswithfigostageib1cervicalcancer AT cailiangzhi riskfactorassessmentoflymphnodemetastasisinpatientswithfigostageib1cervicalcancer AT xieyongjin riskfactorassessmentoflymphnodemetastasisinpatientswithfigostageib1cervicalcancer AT gaoqiao riskfactorassessmentoflymphnodemetastasisinpatientswithfigostageib1cervicalcancer AT sunpengming riskfactorassessmentoflymphnodemetastasisinpatientswithfigostageib1cervicalcancer |